BACKGROUND AND PURPOSE: Mobilization of bone marrow-derived stem cells by granulocyte colony stimulating factor (G-CSF) supports hepatic regeneration and may augment clinical improvement in patients with acute-on-chronic liver failure (ACLF). The aim of this study is to assess the impact of G-CSF on complications and transplant-free survival in patients with ACLF. METHODS:Thirty-two patients with ACLF defined by Asian Pacific Association for the Study of the Liver (APASL) criteria were openly randomized to control (group A) or intervention (group B) receiving G-CSF (5 μg/kg/day, for 6 consecutive days) in addition to standard medical therapy with antiviral drugs. The patients were followed for 90 days. RESULTS: Simultaneous use of G-CSF and antiviral drugs in hepatitis B virus (HBV) ACLF significantly improved survival over antiviral drugs alone. Incidence of hepatorenal syndrome and hyponatremia were reduced due to use of G-CSF. Baseline parameters of the two groups of patients were comparable. Child-Turcotte-Pugh (CTP) and Model for End-Stage Liver Disease (MELD), disease severity scores improved in patients treated with G-CSF, with significant difference only for the CTP score at 90 days follow-up. In addition, mean white blood cell (WBC) count at day 15 was significantly higher in G-CSF group in absence of infection compared with control group. CONCLUSIONS:G-CSF therapy improved survival and clinical recovery in HBV-ACLF. G-CSF therapy also prevented renal failure and hyponatremia. We strongly recommend use of G-CSF therapy in addition to standard medical therapy.
RCT Entities:
BACKGROUND AND PURPOSE: Mobilization of bone marrow-derived stem cells by granulocyte colony stimulating factor (G-CSF) supports hepatic regeneration and may augment clinical improvement in patients with acute-on-chronic liver failure (ACLF). The aim of this study is to assess the impact of G-CSF on complications and transplant-free survival in patients with ACLF. METHODS: Thirty-two patients with ACLF defined by Asian Pacific Association for the Study of the Liver (APASL) criteria were openly randomized to control (group A) or intervention (group B) receiving G-CSF (5 μg/kg/day, for 6 consecutive days) in addition to standard medical therapy with antiviral drugs. The patients were followed for 90 days. RESULTS: Simultaneous use of G-CSF and antiviral drugs in hepatitis B virus (HBV) ACLF significantly improved survival over antiviral drugs alone. Incidence of hepatorenal syndrome and hyponatremia were reduced due to use of G-CSF. Baseline parameters of the two groups of patients were comparable. Child-Turcotte-Pugh (CTP) and Model for End-Stage Liver Disease (MELD), disease severity scores improved in patients treated with G-CSF, with significant difference only for the CTP score at 90 days follow-up. In addition, mean white blood cell (WBC) count at day 15 was significantly higher in G-CSF group in absence of infection compared with control group. CONCLUSIONS:G-CSF therapy improved survival and clinical recovery in HBV-ACLF. G-CSF therapy also prevented renal failure and hyponatremia. We strongly recommend use of G-CSF therapy in addition to standard medical therapy.
Authors: Christine Bernsmeier; Oltin T Pop; Arjuna Singanayagam; Evangelos Triantafyllou; Vishal C Patel; Christopher J Weston; Stuart Curbishley; Fouzia Sadiq; Nikhil Vergis; Wafa Khamri; William Bernal; Georg Auzinger; Michael Heneghan; Yun Ma; Wayel Jassem; Nigel D Heaton; David H Adams; Alberto Quaglia; Mark R Thursz; Julia Wendon; Charalambos G Antoniades Journal: Gastroenterology Date: 2014-12-03 Impact factor: 22.682
Authors: Mamun Al Mahtab; Sheikh Mf Akbar; Masuda Begum; Md A Islam; Md A Rahim; Sheikh M Noor-E-Alam; Md A Alam; Faiz A Khondaker; Ahmed L Moben; Masuda Mohsena; Md Sakirul I Khan; Md Z Huq; Swati Munshi; Ashraful Hoque; Sheikh A Haque Journal: Euroasian J Hepatogastroenterol Date: 2019-02-01
Authors: Abdullah Al Mukit; Mamun Al Mahtab; Md Abdur Rahim; Seikh Mohammad Noor-E-Alam; Dulal Chandra Das; Ahmed Lutful Moben; Faiz Ahmad Khondaker; Md Ashraful Alam; Rokshana Begum; Mohammad Ekramul Haque; Md Atikul Islam; Ayub Al Mamun; Sheikh Mohammad Fazle Akbar Journal: Euroasian J Hepatogastroenterol Date: 2022 Jan-Jun
Authors: Wei Huang; Yuanji Ma; Lingyao Du; Shuang Kang; Chang-Hai Liu; Lang Bai; Xuezhong Lei; Hong Tang Journal: Ann Saudi Med Date: 2021-12-02 Impact factor: 1.526